Novartis Partners with PTC for Huntington's Drug PTC518 in $2.9 Billion Deal

The Novartis and PTC Therapeutics deal involves a significant investment aimed at the development and commercialization of PTC518, an experimental drug for Huntington's disease. Novartis will provide an upfront payment of $1 billion, with additional potential milestone payments of up to $1.9 billion, totaling up to $2.9 billion. In this agreement, PTC retains a 40% share of profits in the U.S. and will earn tiered royalties internationally. The arrangement positions Novartis to further pursue neuroscience innovation by leveraging its global capabilities alongside PTC's expertise in small molecule splicing therapies. The collaborative endeavor not only reflects Novartis's commitment to reinvest in the R&D space but also strategically strengthens PTC's ongoing research initiatives[1][2][3].